Product/Composition:- | Sofosbuvir & Ledipasvir Tablets |
---|---|
Strength:- | 90 mg Ledipasvir / 400 mg Sofosbuvir |
Form:- | Tablet |
Reference Brands:- | Harvoni® (EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Sofosbuvir & Ledipasvir Tablets (Harvoni®) are a once-daily oral treatment for chronic Hepatitis C infection. Combining 400 mg Sofosbuvir and 90 mg Ledipasvir, this FDA- and EMA-approved antiviral effectively stops viral replication. Widely used in the US and EU, it offers a safe, well-tolerated cure, making it essential for pharma B2B suppliers and healthcare providers targeting Hepatitis C management.
Sofosbuvir & Ledipasvir Tablets are a fixed-dose oral antiviral combination used to treat chronic Hepatitis C virus (HCV) infection. Marketed globally under the brand name Harvoni®, this potent direct-acting antiviral (DAA) therapy combines 90 mg Ledipasvir and 400 mg Sofosbuvir to inhibit viral replication. Approved by the US FDA and EMA, it offers a highly effective, once-daily regimen with excellent safety and tolerability profiles. Essential for pharma B2B suppliers and healthcare providers in the EU and US, Sofosbuvir & Ledipasvir supports global efforts to eliminate Hepatitis C through curative treatment options.